ASPSCR1 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: It is worth mentioning that previous literature reported that Xp11.2 tRCC with ASPL-TFE3 fusion are more prone to present at advanced stage than cases with PRCC-TFE3 (14), however, in our cohort, although positive lymph node status at surgery is more common in ASPL-TFE3 cases (6/11, 54.5%), there was no statistically significant difference in pM stage at the last follow‐up between ASPL-TFE3 and PRCC-TFE3 cases.